The influence on gene-expression profiling of osteoblasts behavior following treatment with the ionic products of sintered beta-dicalcium pyrophosphate dissolution.
Sintered dicalcium pyrophosphate (SDCP) is biocompatible to bone tissue both in the in vivo and in vitro model. However, the molecular mechanisms that mediated these processes have yet to be identified. In this study, we investigated the influence of SDCP ions on in vitro osteoblasts behavior. The powder of sintered beta-dicalcium pyrophosphate (SDCP) was dissolved by HCl and then diluted into different concentration of solutions by culture medium used in the osteoblast cell culture. The effects of various concentration of SDCP on bone cell activities were evaluated by using MTT assay. For the differentiation of osteoblasts, alkaline phosphatase (AP) staining, von Kossa stain for mineralized nodules and bone markers messenger ribonucleic acid (mRNA) isolation and identification were performed at 3h, days 1, 3, 7 and 14. In the presence of 10(-8)M SDCP for 14 days, the osteoblasts population was still significantly higher than that of control. In the qualitative analysis for the formation of AP staining colonies and mineralization nodules formation were not affected by SDCP ions. When osteoblasts cultured in the presence of 10(-8)M SDCP ions, the osteocalcin mRNA expression was up-regulated; while the collagen, osteonectin and osteopontin mRNA expression were down-regulated. In this study, we demonstrated that the elevated concentration of calcium and pyrophosphate ions can activate genes of the bone cells. This study will contribute to a better understanding of cell/biomaterial interactions and mechanisms that SDCP affect the bone cells.
Sun
Jui-Sheng
JS
Department of Biomedical Engineering, National Taiwan University Hospital, Taipei, Taiwan, ROC.
Chang
Walter Hong-Shong
WH
Chen
Li-Ting
LT
Huang
Yi-Chau
YC
Juang
Lee-Wei
LW
Lin
Feng-Huei
FH
D000818:Animals; D000831:Animals, Newborn; D001672:Biocompatible Materials / Q000494:pharmacology*; D002131:Calcium Pyrophosphate / Q000737:chemistry* / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D024042:Collagen Type I / Q000378:metabolism*; D005786:Gene Expression Regulation / Q000187:drug effects*; D008422:Materials Testing / Q000379:methods*; D010006:Osteoblasts / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism*; D015676:Osteonectin / Q000378:metabolism*; D053495:Osteopontin; D011208:Powders / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012795:Sialoglycoproteins / Q000378:metabolism*; D012886:Skull
D001672:Biocompatible Materials; D024042:Collagen Type I; D015676:Osteonectin; D011208:Powders; D012795:Sialoglycoproteins; C506897:Spp1 protein, rat; C476842:sintered beta-dicalcium pyrophosphate; D053495:Osteopontin; D002131:Calcium Pyrophosphate